

**THRU ONLINE FILING**

August 12, 2022

BSE Ltd.  
Phiroze Jeejeebhoy Towers  
Dalal Street  
Mumbai 400 023  
Scrip Code – 524494

National Stock Exchange India Limited,  
Exchange Plaza, C-1, Block-G,  
Bandra Kurla Complex, Bandra – (East).  
Mumbai-400051.  
Scrip Code : IPCALAB

Dear Sir,

**Sub: Disclosure of Related Party Transactions pursuant to Regulation 23(9) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.**

In accordance with Regulation 23(9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the disclosure of related party transactions for the half year ended March 31, 2022.

This is for your information and records.

Thanking you

Yours faithfully  
For Ipca Laboratories Limited



Harish P. Kamath  
Corporate Counsel & Company Secretary

Encl: a/a

Ipca Laboratories Ltd.  
www.ipca.com

<b>General information about company</b>	
Name of The Company	Ipca Laboratories Limited
BSE Scrip Code	524494
NSE Symbol	IPCALAB
MSE Symbol	NA
Date of Start of Financial Year	01-04-2021
Date of End of Financial Year	31-03-2022
Reporting Period	Second half yearly
Date of Start of Reporting Period	01-10-2021
Date of End of Reporting Period	31-03-2022
Level of rounding to be used in disclosing related party transactions	Crores
Whether the company has any related party?	Yes
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure?	Yes

(I) We declare that the acceptance of fixed deposits by the banks/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public	NA
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of bank's staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure.	NA
(III) Whether the company is a 'high value debt listed entity' according to regulation 15 (1A)?	No
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?	
<b>(b) If answer to above question is No, please explain the reason for not complying.</b>	

Related Party Transactions																				
S No											Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.									
	Details of the party (listed entity/subsidiary) entering into the transaction		Details of the counterparty		Type of related party transaction	Details of other related party transaction	Value of the related party transaction as approved by the audit committee	Remarks on approval by audit committee	Value of transaction during the reporting period	In case monies are due to either party as a result of the transaction		In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments				Details of the loans, inter-corporate deposits, advances or investments				Notes
	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary						Opening balance	Closing balance	Nature of indebtedness (loan/issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/advance/intercorporate deposit/investment)	Interest Rate (%)	Tenure	Secured/unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (end usage)	
1.	Ipca Laboratories Ltd	Krebs Biochemicals & Industries Ltd.	Associates	Purchase of goods or services			None	49.74	0	0										
2	Ipca Laboratories Ltd	Krebs Biochemicals & Industries Ltd.	Associates	Sale of goods or services			None	16.29	7.3	12.65										
3	Ipca Laboratories Ltd	Krebs Biochemicals & Industries Ltd.	Associates	Sale of fixed assets			None	0.83												
4	Ipca Laboratories Ltd	Krebs Biochemicals & Industries Ltd.	Associates	Loan			None	2	79.93	2					Loan	0.08	3 Years	Unsecured	Business	

5	Ipca Laboratories Ltd	Krebs Biochemicals & Industries Ltd.	Associates	Investment			None	95.83	108.76	208.76					Investment	0	0	Unsecured	Business	
6	Ipca Laboratories Ltd	Krebs Biochemicals & Industries Ltd.	Associates	Interest received			None	1.66	5.6	7.1										
7	Ipca Laboratories Ltd	Krebs Biochemicals & Industries Ltd.	Associates	Inter-corporate deposit			None	0	45	45					Inter-corporate deposit	0.08	3 Years	Unsecured	Business	
8	Ipca Laboratories Ltd	Krebs Biochemicals & Industries Ltd.	Associates	Any other transaction	Corporate Guarantee Given.		None	0	11	11										
9	Ipca Laboratories Ltd	Krebs Biochemicals & Industries Ltd.	Associates	Advance			None	6.37	6.97	11.41					Advance	0	0	Unsecured	Business	
10	Ipca Laboratories Ltd	Avik pharmaceutical ltd.	Joint Ventures	Purchase of goods or services			None	16.14	-1.85	0										
11	Ipca Laboratories Ltd	Avik pharmaceutical ltd.	Joint Ventures	Sale of goods or services			None	5.01	2.63	1.78										
12	Ipca Laboratories Ltd	Avik pharmaceutical ltd.	Joint Ventures	Loan			None	0	12.78	12.38					Loan	0.11	3 Years	Unsecured	Business	
13	Ipca Laboratories Ltd	Avik pharmaceutical ltd.	Joint Ventures	Investment			None	0.11	6.84	6.95					Investment	0	0	Unsecured	Business	
14	Ipca Laboratories Ltd	Avik pharmaceutical ltd.	Joint Ventures	Interest received			None	0.78	0.13	0										
15	Ipca Laboratories Ltd	Avik pharmaceutical	Joint Ventures	Inter-corporate			None	0	1.4	1.4					Inter-corporate	0.12	3 Year	Unsecured	Business	



